Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma | Journal for ImmunoTherapy of Cancer

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

PDF +
Supplementary
Material

Clinical/translational cancer immunotherapy

Original research

Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma

Online download statistics by month:

Online download statistics by month: September 2022 to September 2024

	Abstract	Full	Pdf
Sep 2022	504	535	238
Oct 2022	430	436	163
Nov 2022	212	228	89
Dec 2022	212	220	68
Jan 2023	147	148	56
Feb 2023	191	194	85
Mar 2023	152	152	65
Apr 2023	186	190	51
May 2023	126	127	49
Jun 2023	186	193	71
Jul 2023	132	132	51
Aug 2023	127	130	59
Sep 2023	87	91	33
Oct 2023	95	96	47
Nov 2023	119	119	54
Dec 2023	154	155	72
Jan 2024	156	158	84
Feb 2024	92	92	52
Mar 2024	129	129	72
Apr 2024	150	151	64
May 2024	144	147	169
Jun 2024	118	117	65
Jul 2024	151	157	65
Aug 2024	101	101	52
Sep 2024	94	95	45
Total	4195	4293	1919